Scancell Holdings PLC
LSE:SCLP
Intrinsic Value
Scancell Holdings Plc engages in the development of novel therapeutic vaccines for the treatment of cancer. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of SCLP.
Scancell Holdings PLC's market capitalization is 78.6m GBX.
SCLP stock price is 9.6 GBX.
SCLP.
SCLP. Open DCF Valuation
SCLP. Open Relative Valuation
SCLP has upside potential of 163% compared to the average analyst price target.
Open Wall St Estimates
SCLP has negative Gross Profit for the last twelve months.
SCLP has positive Net Debt. This means that the company has more debt (20m GBP) than cash and short-term investments (13m GBP).
SCLP's ROE (Return on Equity) has significantly decreased in the last 3 years from -39% to -320%, and is approaching profitability.
SCLP's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -111% to -154%, and is approaching profitability.
SCLP's long-term liabilties (31m GBP) exceed its long-term assets (22m GBP).
SCLP has negative Operating Income for the last twelve months.
SCLP has negative Net Income for the last twelve months.
SCLP's ROE (Return on Equity) for the past 12 months is negative and is equal to -320%.
SCLP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -154%.
SCLP has negative Free Cash Flow for the last twelve months.
SCLP has negative three-year average ROE (Return on Equity): -113%. The company is not efficient at transforming stockholders' equity into net income.
SCLP has negative three-year average ROIC (Return on Invested Capital): -140%. The company is not efficient at using invested capital to generate operating income.
SCLP's short-term assets (17m GBP) exceed its short-term liabilties (2m GBP).
SCLP's D/E (Debt to Equity) is very low and is equal to -2.33.
SCLP's Altman Z-Score is very low and is equal to -5.27.
SCLP doesn't generate enough operating income (-18m GBP) to safely cover interest payments on its debt (540k GBP).
Fundamental Analysis
Scancell Holdings PLC
Balance Sheet Decomposition
Scancell Holdings PLC
| Current Assets | 17m |
| Cash & Short-Term Investments | 13.1m |
| Receivables | 3.9m |
| Non-Current Assets | 5.2m |
| PP&E | 1.8m |
| Intangibles | 3.4m |
| Current Liabilities | 2m |
| Accounts Payable | 1.7m |
| Other Current Liabilities | 306k |
| Non-Current Liabilities | 28.6m |
| Long-Term Debt | 19.5m |
| Other Non-Current Liabilities | 9.1m |
Earnings Waterfall
Scancell Holdings PLC
|
Revenue
|
0
GBP
|
|
Cost of Revenue
|
-530k
GBP
|
|
Gross Profit
|
-530k
GBP
|
|
Operating Expenses
|
-17.5m
GBP
|
|
Operating Income
|
-18.1m
GBP
|
|
Other Expenses
|
6.8m
GBP
|
|
Net Income
|
-11.3m
GBP
|
Free Cash Flow Analysis
Scancell Holdings PLC
What is Free Cash Flow?
SCLP Profitability Score
Profitability Due Diligence
Scancell Holdings PLC's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Scancell Holdings PLC's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
SCLP Solvency Score
Solvency Due Diligence
Scancell Holdings PLC's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Scancell Holdings PLC's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SCLP Price Targets Summary
Scancell Holdings PLC
According to Wall Street analysts, the average 1-year price target for
SCLP
is 25.23 GBX
with a low forecast of 21.21 GBX and a high forecast of 31.5 GBX.
Shareholder Return
SCLP Price
Scancell Holdings PLC
| Average Annual Return | 51.82% |
| Standard Deviation of Annual Returns | 37.43% |
| Max Drawdown | -70% |
| Market Capitalization | 78.6m GBX |
| Shares Outstanding | 819 342 200 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Scancell Holdings PLC
Country
Industry
Market Cap
Dividend Yield
Description
Scancell Holdings Plc engages in the development of novel therapeutic vaccines for the treatment of cancer. The company is headquartered in Oxford, Oxfordshire and currently employs 25 full-time employees. The company went IPO on 2010-07-30. The firm is focused on developing immunotherapies for the treatment of cancer and infectious disease. The Company’s technology includes ImmunoBody, Moditope, and AvidiMab, Its product pipeline includes SCIB1, SCIB2, Modi-1, Modi-2 and SCOV1& SCOV2 (COVIDITY). Its lead ImmunoBody cancer vaccine, SCIB1, is developed for the treatment of patients with metastatic melanoma. SCIB1 consists of SCIB1-001 and SCIB1-002. Its SCIB2 is the second cancer vaccine based on the ImmunoBody technology. SCIB2 vaccine is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer (NSCLC). Modi-1 is based on Moditope platform, which is composed of a combination of three peptides from two target antigens that are commonly modified in cancer cells. Modi-2 targets homocitrullinated cancer antigens, to address different cancer indications to Modi-1, including tumors.
You don't have any saved screeners yet
